1. Introduction {#sec1-toxins-08-00169}
===============

Staphylococcal food poisoning (SFP) is the most prevalent foodborne intoxication worldwide. The Centers for Disease Control estimate that 240,000 cases per year occur in the US alone, leading to 1000 hospitalizations and six deaths \[[@B1-toxins-08-00169]\]. Upon ingestion, staphylococcal enterotoxins (SEs) secreted by *Staphylococcus (S.) aureus* during growth in the food matrix elicit symptoms of acute gastroenteritis such as violent vomiting and diarrhea \[[@B2-toxins-08-00169]\]. *S. aureus* strains can produce one or several of the five major SEs (SEA, SEB, SEC, SED, SEE).

Pronounced strain-specific variation of SE mRNA and protein levels has been reported, in particular under conditions of environmental stress encountered in the food matrix \[[@B3-toxins-08-00169],[@B4-toxins-08-00169],[@B5-toxins-08-00169],[@B6-toxins-08-00169]\]. Expression of the phage-encoded SEA was shown to be linked to the life cycle of the phage \[[@B7-toxins-08-00169],[@B8-toxins-08-00169]\] and to nucleotide sequence variation in the *sea* gene and upstream promoter region \[[@B9-toxins-08-00169]\].

There is some data on the variation of the enterotoxin gene and promoter sequences of SEB, SEC, and SED. Previous studies characterizing the *seb* and *sed* promoters have shown that the region from −98 to −59 is required for the expression and regulation of *seb* \[[@B10-toxins-08-00169]\] and that the region from −34 to +18 is required for *sed* promoter function \[[@B11-toxins-08-00169]\].

The *seb* gene resides in one of seven different *S. aureus* pathogenicity islands (SaPIs) \[[@B12-toxins-08-00169],[@B13-toxins-08-00169],[@B14-toxins-08-00169]\]. Strains harboring different SaPIs carrying *seb* were reported to vary in SEB levels produced \[[@B13-toxins-08-00169]\]. To date, five different allelic variants of SEB have been described that vary in biological activity \[[@B15-toxins-08-00169]\].

The *sec* gene can also be located in different SaPIs, including SaPIn1, SaPIm1, SaPImw2, and SaPIbov1. Four variants of SEC (SEC1-4) associated with human *S. aureus* strains have been described, as well as the host-specific variants SEC-bovine and SEC-ovine \[[@B16-toxins-08-00169],[@B17-toxins-08-00169],[@B18-toxins-08-00169],[@B19-toxins-08-00169]\].

The *sed* gene and reporter sequences seem to be highly conserved and are located on a pIB485-related 27.6 kb plasmid \[[@B20-toxins-08-00169]\]. However, strains harboring a single base deletion in various locations in the *sed* sequence have been reported in *S. aureus* isolates obtained from human hosts \[[@B21-toxins-08-00169],[@B22-toxins-08-00169],[@B23-toxins-08-00169],[@B24-toxins-08-00169]\].

The aim of this study was to analyze promoter and gene sequences of *seb*, *sec*, and *sed* from *S. aureus* strains originating from different sources. Data on the variability of enterotoxin nucleotide sequences in strains from different hosts can represent an important further step in understanding strain-specific variation in SE expression, and in monitoring the evolution of *S. aureus* pathogenicity and host adaptation.

2. Results {#sec2-toxins-08-00169}
==========

2.1. Seb Promoter and Gene Sequences {#sec2dot1-toxins-08-00169}
------------------------------------

The *seb* promoter and gene sequences of 12 strains were determined and alignments of all sequences are provided as a supplementary file ([Figure S1](#app1-toxins-08-00169){ref-type="app"}). Five variants of the *seb* promoter (*seb*~p~ v1--v5) were detected that differed at several nucleotide positions. While −35 (TGAATA) and −10 (TATATT) *seb* promoter elements were identical in all tested strains, sequence variation was detected in the region essential for *seb* expression that is located between 59 and 93 nucleotides upstream of the transcription start site. The *seb* promoter variants *seb*~p~ v1, v2, and v5 exhibited nucleotides GT (positions −47, −46), AT (positions −23, −22), and A (position −18), while *seb*~p~ v3 and v4 exhibited nucleotides AA (position −47, −46), GA (positions −23, −22), and G (position −18). Promoter variant *seb*~p~ v4 and v5 did not correspond to any known *seb* promoter sequences in GenBank.

The *seb* gene ORF exhibited a length of 801 bp in all 12 strains. Nucleotide sequence variation was found at numerous positions (9, 19, 26, 44, 52, 62, 84, 87, 121, 162, 165, 351, 393, 405, 456, 484, 513, 522, 543, 621, 656, 738, 745), leading to the identification of four different variants (*seb* v1--v4). Two strains (RKI4 and SAI33) harbored the novel variant v3. The different *seb* nucleotide sequences resulted in three different amino acid variants (266 amino acid precursor), which were identical to known amino acid variants of reference strains (COL, IVM10, No. 10). An alignment of the respective amino acid sequences and reference sequences is provided in [Figure 1](#toxins-08-00169-f001){ref-type="fig"}.

Screening of strains representing the different *seb* variants for production of SEB using SET-RPLA (Oxoid, Pratteln, Switzerland) showed that all variants are expressed.

2.2. Sec Promoter and Gene Sequences {#sec2dot2-toxins-08-00169}
------------------------------------

The *sec* promoter and gene sequences were determined in 10 strains and alignments of all sequences are provided as a supplementary file ([Figure S2](#app1-toxins-08-00169){ref-type="app"}). The −35 (TTGAA) and −10 (TATATTT) *sec* promoter elements were identical in all tested strains.

The *sec* ORF exhibited a length of 801 bp in all strains. Isolates obtained from nasal colonization and foodborne outbreaks harbored a *sec* variant (v1) identical to the previously described SEC-2 subtype. All bovine strains exhibited *sec* v2 identical with the SEC-bovine subtype. For SAI3, a human infection isolate, a *sec* variant (*sec* v3) identical to subtype SEC-1 was found. For SAI48, a strain also linked to an infection in a human patient, a novel nucleotide sequence similar to SEC-2, with the exception of a point mutation at position 87 (T -\> C), was identified. The four nucleotide sequence variants resulted in three different predicted variants of the 266-amino-acid precursor. Nucleotide sequence variants v1 and the novel variant v4 both resulted in the amino acid variant *sec*~aa~ v1 (SEC-2), while v2 resulted in *sec*~aa~ v2 (SEC-bovine), and v3 resulted in *sec*~aa~ v3 (SEC-1), respectively. An alignment of the respective amino acid sequences and reference sequences is provided as [Figure 2](#toxins-08-00169-f002){ref-type="fig"}.

Screening the strains exhibiting *sec* for SEC production using SET-RPLA led to detection of SEC in all strains, showing that all *sec* variants are expressed.

2.3. Sed Promoter and Gene Sequences {#sec2dot3-toxins-08-00169}
------------------------------------

The sequences of the *sed* promoter and gene were determined in 12 strains and alignments of all sequences are provided as a supplementary file ([Figure S3](#app1-toxins-08-00169){ref-type="app"}). The −35 (ATGAAA) and −10 (TATAA) promoter elements were identical in all tested strains.

The *sed* sequences were also highly conserved. However, point mutations were observed in strain SANC30 (position 198 G -\> A, position 364 T -\> G) and in strains BW10, RKI1, RKI2, and SAR35 (position 383 G -\> A). In total, four different amino acid variants were detected, none of which was 100% identical to the common *sed* plB485 reference sequence (Genbank accession number M28521.1). SANC30 exhibited a novel amino acid sequence (variant 4) with two amino acid changes (position 100 E -\> K, position 121 Y -\> D) that did not correspond to any sequence in the GenBank database. An alignment of the respective amino acid sequences and reference sequences is provided in [Figure 3](#toxins-08-00169-f003){ref-type="fig"}.

All three tested rabbit isolates harbored the same *sed* nucleotide sequence variant (v3), which exhibits a deletion in *sed* at nucleotide position 521, resulting in a premature stop codon at amino acid position 180. To confirm the possibility of a host-specific variant, an additional three *sed+* rabbit strains were sequenced, which harbored the same truncated variant.

Screening of strains representing the different *sed* variants for production of SED by SET-RPLA showed that not only the complete *sed* variants but also the truncated *sed* v3 were expressed. However, for the strains harboring the truncated *sed* variant, SED levels were far lower, with only the first dilution in the dilution series yielding a weakly positive test result. Four rabbit strains harboring the truncated *sed* v3 variant were screened. While SED was detected in three of these strains (SAK8, SAK11, SAK13), one strain (SAK64) did not yield a positive result for SED production. While all *sed+* rabbit strains represent the same clonal complex (CC5), SAK64 was the only rabbit strain of *spa* type t160.

3. Discussion {#sec3-toxins-08-00169}
=============

In this study, several new variants of *seb, sec,* and *sed* enterotoxin genes and promoters were detected. Sequencing of *seb,* *sec*, and *sed* promoter regions revealed that promoter sequences were highly conserved in *sec* and *sed*. In contrast, several variable positions were observed in the *seb* promoter region, including the region required for *seb* transcription and expression. This is consistent with findings by Sato'o *et al.* \[[@B13-toxins-08-00169]\], reporting high variability in *seb* upstream sequences from different strains. In the same study, several novel SaPIs carrying *seb* were identified and linked to differences in SEB production levels. However, the differences in *seb* promoter regions did not correlate with SEB production in a statistically significant manner \[[@B13-toxins-08-00169]\].

Comparative analysis of the nucleotide sequences of the *seb*, *sec*, and *sed* genes showed that *sed* sequences were more conserved than *seb* and *sec* sequences. The length of the *seb* and *sec* coding sequences determined in this study was consistent with previous reports \[[@B18-toxins-08-00169],[@B25-toxins-08-00169],[@B26-toxins-08-00169]\].

Most of the residues that are conserved throughout all SEs are either centrally located or can be found at the *C*-terminal end \[[@B27-toxins-08-00169]\]. This is also consistent with the findings in this study for the amino acid prediction of *seb,* and *sec* variants, indicating that amino acid exchanges were more likely to occur at the *N*-terminus. However, for SED*,* the highest degree of amino acid variability detected in this study was centrally located*.*

Predicting altered functionality based on the detected amino acid exchanges is challenging, as emetic activity is still poorly understood. While lack of the disulfide loop was suggested to result in no or lower emetic activity, it has been shown that the disulfide bond is not a prerequisite for emetic activity \[[@B28-toxins-08-00169]\]. Concerning superantigenic activity, ovine and bovine SEC variants were reported to be strongly altered in function due to only three amino acid changes resulting in host-dependent superantigenicity \[[@B27-toxins-08-00169]\]. With regard to antigenicity, it was shown that SE variants differing in several residues, such as the SEC variants identified in FRI909 and FRI913 (9 differing residues), can still be antigenetically indistinguishable \[[@B27-toxins-08-00169]\].

For SEC, four variants (SEC1-4) associated with human *S. aureus* isolates have been reported, as well as the host-specific variants SEC-bovine and SEC-ovine \[[@B16-toxins-08-00169],[@B17-toxins-08-00169],[@B18-toxins-08-00169],[@B19-toxins-08-00169]\]. In contrast, subtypes of *seb* and the different SaPIs associated with these subtypes have only recently gained attention \[[@B13-toxins-08-00169],[@B15-toxins-08-00169]\]. Kohler *et al.* demonstrated the existence of multiple SEB variants that differed in their ability to activate subsets of T cells and in their effects on the proliferation of peripheral blood mononuclear cells and rabbit splenocytes \[[@B15-toxins-08-00169]\].

In this study, a novel *seb* nucleotide sequence variant (*seb* v3) was identified in two of the tested strains (RKI4 and SAI33). However, the *seb* v3 nucleotide sequence variant results in a known SEB amino acid sequence identical to reference strain No. 10. For *sec*, one novel *sec* nucleotide sequence (*sec* v4) was detected in one strain (SAI48). Amino acid sequence prediction showed that *sec* v4 results in an amino acid sequence identical to the one of *sec* v1, which is also known as SEC-2 (reference strain 79_S10). For *sed*, one novel nucleotide sequence (*sed* v4) was determined in a strain associated with human nasal colonization (SANC30). The novel *sed* v4 nucleotide sequence variant results in a novel amino acid sequence variant of SED that was not previously described elsewhere (*sed~aa~* v4).

In this study, a variant of *sed* was identified which was present in all tested rabbit isolates (*n* = 6). This variant *sed* v3 exhibited a deletion that resulted in a premature stop codon and a truncated *sed* amino acid precursor. In foodborne outbreak isolates, deletions at nucleotide positions 150 \[[@B21-toxins-08-00169]\] and 514 \[[@B22-toxins-08-00169]\] resulting in a premature stop codon have been reported. A deletion in *sed* identical to the one seen in the rabbit isolates in this study (nucleotide position 521) has been reported in *S. aureus* isolates originating from humans and from food \[[@B23-toxins-08-00169],[@B24-toxins-08-00169]\]. While Lis *et al.* confirmed transcription of *sed* by qPCR, they could not detect SED protein by ELISA or Western blotting \[[@B24-toxins-08-00169]\]. In contrast, in this study, three of four rabbit strains tested with truncated *sed* variants yielded a weak, but positive result for SED in the SET-RPLA assay. The deletion in *sed* may impair the functionality of the protein and recognition by various detection methods.

4. Conclusions {#sec4-toxins-08-00169}
==============

The sequence data generated in this study extends the current knowledge on sequence variation in enterotoxin genes of *S. aureus* strains isolated from various sources. Several novel variants of enterotoxin promoter and gene nucleotide sequences were described, and a novel amino acid sequence variant of SED was identified in a strain obtained from a nasal carrier. In addition, the results presented in this study confirm previous reports of host-specific enterotoxin variants such as SEC-bovine. Interestingly, all *sed+* rabbit strains tested in this study harbored a *sed* variant that exhibited a deletion in *sed* leading to a premature stop codon.

The data generated represents a further step towards improved understanding of strain-specific differences in enterotoxin expression and host-specific variation in enterotoxin sequences.

5. Materials and Methods {#sec5-toxins-08-00169}
========================

5.1. Bacterial Strains {#sec5dot1-toxins-08-00169}
----------------------

The *S. aureus* isolates used in this study originated from SFP outbreaks, asymptomatic nasal colonization or cases of infections in humans, as well as rabbit carcasses and bovine mastitis milk. Isolates were selected from a large collection of well-characterized *S. aureus* strains*,* for which DNA microarray enterotoxin hybridization patterns, *spa* types, and clonal complexes had been previously determined and published \[[@B14-toxins-08-00169],[@B28-toxins-08-00169],[@B29-toxins-08-00169],[@B30-toxins-08-00169],[@B31-toxins-08-00169]\]. Detailed information on all *S. aureus* strains used in this study is provided in [Table 1](#toxins-08-00169-t001){ref-type="table"}.

5.2. DNA Extraction and PCR Amplification {#sec5dot2-toxins-08-00169}
-----------------------------------------

Frozen stock cultures (−80 °C) of *S. aureus* strains were resuscitated by plating on 5% sheep blood agar and incubation at 37 °C over night. Bacterial DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) following the manufacturer′s instructions.

PCR was performed using the Phusion High-Fidelity System (Thermo Scientific, Reinach, Switzerland) using a total reaction volume of 50 μL. All primers and primer-pair specific annealing temperatures are provided as supplemental material ([Table S1](#app1-toxins-08-00169){ref-type="app"}). For each reaction, 5 μL buffer, 2 μL DMSO, 1 μL dNTP mix, 2 μL of each primer (*c* = 10 μM), 0.5 μL Phusion High-Fidelity DNA polymerase, 36.5 μL Aq.B., and 1 μL DNA template were used. PCR cycling conditions included: 5 min hot start at 95 °C, followed by 30 amplification cycles (denaturation at 95 °C for 30 s, annealing at the primer-specific annealing temperature for 30 s, elongation at 72 °C for 75 s), a final elongation step at 72 °C for 10 min, and a cooling step. Target-specific amplification was confirmed by electrophoresis using a 1% agarose gel.

5.3. PCR Purification and Sequencing {#sec5dot3-toxins-08-00169}
------------------------------------

PCR amplicons were purified using the MinElute PCR Purification Kit (Qiagen, Hilden, Germany) and sequencing was outsourced (Microsynth, Balgach, Switzerland). The acquired sequences were analyzed using CLC Main Workbench software (Version 6.9, CLC Bio/Qiagen, Aarhus, Denmark, 2012) and were compared to reference nucleotide sequences imported from GenBank (NCBI). Novel variants of enterotoxin promoter or gene sequences were subsequently submitted to GenBank.

5.4. Toxin Detection by SET-RPLA {#sec5dot4-toxins-08-00169}
--------------------------------

Expression of different *seb*, *sec*, and *sed* variants was assessed in selected strains using the SET-RPLA kit (Oxoid). Enterotoxins were detected using bacterial culture filtrates (0.2 μm filter, Whatman, Sigma-Aldrich, Buchs, Switzerland) from stationary phase cultures of each strain in Luria Bertrani (LB, Becton Dickinson, Allschwil, Switzerland) broth (37 °C, 225 rpm shaking, 20 h of incubation) in accordance with the manufacturer's instructions. Culture filtrates were diluted in a five-fold dilution series for semi-quantitative detection of SEB, SEC, and SED. For *seb,* strains KLT6, SANC49, SANC14, SAI45, RKI4, and SAI40 were tested for SEB expression. All *sec* strains were assayed for SEC expression. For *sed,* strains BW10, RKI1, RKI2, KLT8, SAK8, SAK11, SAK13, and SAK64 were tested for SED expression.

5.5. Amino Acid Identity {#sec5dot5-toxins-08-00169}
------------------------

A pairwise amino acid identity comparison between all SEB, SEC, and SED enterotoxin variants is provided in [Table 2](#toxins-08-00169-t002){ref-type="table"}.

5.6. Accession Numbers {#sec5dot6-toxins-08-00169}
----------------------

All variants of promoter and gene sequences were submitted to GenBank and can be accessed using accession numbers KX168612--KX168635. Promoter sequence variants are available for *seb* variants (*seb*~p~ v1 = KX168623, *seb*~p~ v2 = KX168624, *seb*~p~ v3 = KX168625, *seb*~p~ v4 = KX168626, *seb*~p~ v5 = KX168627), *sec* variants (*sec*~p~ v1 = KX168633, *sec*~p~ v2 = KX168634, *sec*~p~ v3 = KX168635), and *sed* variants (*sed*~p~ v1 = KX168616, *sed*~p~ v2 = KX168617, *sed*~p~ v3 = KX168618). Sequence variants are available for the *seb* gene (*seb* v1 = KX168628, *seb* v2 = KX168629, *seb* v3 = KX168630, *seb* v4 = KX168631, *seb* v5 = KX168632), the *sec* gene (*sec* v1 = KX168612, *sec* v2 = KX168613, *sec* v3 = KX168614, *sec* v4 = KX168615), and the *sed* gene (*sed* v1 = KX168619, *sed* v2 = KX168620, *sed* v3 = KX168621, *sed* v4 = KX168622).
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###### 

Detailed overview of sequence variants of enterotoxin promoters and genes of all *S. aureus* strains used in this study. In addition, information on other major enterotoxin genes harbored by each strain, the source of the strain, and its assignment to a *spa* type and clonal complex are provided.

  Gene     Strain ID   Identical Reference ^1^    Promoter Variant ^2^ (Reference)   Gene Variant ^2^ (Reference)    Amino Acid Variant (Reference)   Source       Clonal Complex/*spa* Type                                        Reference
  -------- ----------- -------------------------- ---------------------------------- ------------------------------- -------------------------------- ------------ ---------------------------------------------------------------- ----------------------------------------------------------------
  *seb*    KLT6        COL                        *seb*~p~ v1                        *seb* v1                        *seb*~aa~ v1                     SFP ^3^      CC12/t160                                                        \[[@B29-toxins-08-00169]\]
  SANC31   COL         *seb*~p~ v1                *seb* v1                           *seb*~aa~ v1                    Human nasal colonization         CC59/t216    \[[@B30-toxins-08-00169]\]                                       
  SANC49   COL         *seb*~p~ v1                *seb* v1                           *seb*~aa~ v1                    Human nasal colonization         CC59/t216    \[[@B30-toxins-08-00169]\]                                       
  SAK9     COL         *seb*~p~ v1                *seb* v1                           *seb*~aa~ v1                    Rabbit                           CC5/t8456    \[[@B31-toxins-08-00169]\]                                       
  SAK18    COL         *seb*~p~ v1                *seb* v1                           *seb*~aa~ v1                    Rabbit                           CC5/t8456    \[[@B31-toxins-08-00169]\]                                       
  SAI10    COL         *seb*~p~ v1                *seb* v1                           *seb*~aa~ v1                    Human infection                  CC59/t216    \[[@B30-toxins-08-00169]\]                                       
  SAI50    COL         *seb*~p~ v1                *seb* v1                           *seb*~aa~ v1                    Human infection                  CC59/t015    \[[@B30-toxins-08-00169]\]                                       
  SANC14   IVM10       *seb*~p~ v2                *seb* v2                           *seb*~aa~ v2                    Human nasal colonization         CC45/t630    \[[@B30-toxins-08-00169]\]                                       
  RKI4     novel ^4^   *seb*~p~ v3 (No. 10)       *seb* v3 (novel) ^4^               *seb*~aa~ v3 (No. 10)           SFP                              CC9/t733     \[[@B14-toxins-08-00169]\]                                       
  SAI40    novel ^4^   *seb*~p~ v4 (novel) ^4^    *seb* v3 (No. 10)                  *seb*~aa~ v3 (No. 10)           Human infection                  CC15/t084    \[[@B30-toxins-08-00169]\]                                       
  SAI33    novel ^4^   *seb*~p~ v4 (novel) ^4^    *seb* v3 (novel) ^4^               *seb*~aa~ v3 (No. 10)           Human infection                  CC20/t164    \[[@B30-toxins-08-00169]\]                                       
  SAI45    novel ^4^   *seb*~p~ v5 (novel) ^4^    *seb* v4 (IVM10)                   *seb*~aa~ v2 (IVM10)            Human infection                  CC121/t272   \[[@B30-toxins-08-00169]\]                                       
  *sec*    BW10        79_S10                     *sec*~p~ v1                        *sec* v1 = SEC-2                *sec*~aa~ v1 = SEC-2             SFP          CC45/t383                                                        Medical Department of the German Federal Armed Forces, Germany
  LRA1     79_S10      *sec*~p~ v1                *sec* v1 = SEC-2                   *sec*~aa~ v1 = SEC-2            SFP                              CC73/t015    Bavarian State Office of Health and Food Safety, Germany         
  SANC23   79_S10      *sec*~p~ v1                *sec* v1 = SEC-2                   *sec*~aa~ v1 = SEC-2            Human nasal colonization         CC8/t8016    \[[@B30-toxins-08-00169]\]                                       
  SANC48   79_S10      *sec*~p~ v1                *sec* v1 = SEC-2                   *sec*~aa~ v1 = SEC-2            Human nasal colonization         CC45/t015    \[[@B30-toxins-08-00169]\]                                       
  NB6      79_S10      *sec*~p~ v1                *sec* v1 = SEC-2                   *sec*~aa~ v1 = SEC-2            SFP                              CC45/t6969   Bavarian State Office of Health and Food Safety, Germany         
  SAR1     RF122       *sec*~p~ v2                *sec* v2 = SEC-bovine              *sec*~aa~ v2 = SEC-bovine       Bovine mastitis milk             CC151/t529   \[[@B32-toxins-08-00169]\]                                       
  SAR38    RF122       *sec*~p~ v2                *sec* v2 = SEC-bovine              *sec*~aa~ v2 = SEC-bovine       Bovine mastitis milk             CC151/t529   \[[@B32-toxins-08-00169]\]                                       
  SAR50    RF122       *sec*~p~ v2                *sec* v2 = SEC-bovine              *sec*~aa~ v2 = SEC-bovine       Bovine mastitis milk             CC151/t529   \[[@B32-toxins-08-00169]\]                                       
  SAI3     novel ^4^   *sec*~p~ v3 (H-EMRSA-15)   *sec* v3 = SEC-1 (B1085)           *sec*~aa~ v3 = SEC-1 (B1085)    Human infection                  CC8/t148     \[[@B30-toxins-08-00169]\]                                       
  SAI48    novel ^4^   *sec*~p~ v1 (79_S10)       *sec* v4 (novel) ^4^               *sec*~aa~ v1 = SEC-2 (79_S10)   Human infection                  CC5/t002     \[[@B30-toxins-08-00169]\]                                       
  *sed*    KLT8        pSAP074A                   *sed*~p~ v1                        *sed* v1                        *sed*~aa~ v1                     SFP          CC5/t8017                                                        Cantonal Laboratory Thurgau, Switzerland
  SAI8     pSAP074A    *sed*~p~ v1                *sed* v1                           *sed*~aa~ v1                    Human infection                  CC5/t954     \[[@B30-toxins-08-00169]\]                                       
  SAI41    pSAP074A    *sed*~p~ v1                *sed* v1                           *sed*~aa~ v1                    Human infection                  CC5/t8017    \[[@B30-toxins-08-00169]\]                                       
  SAI48    novel ^4^   *sed*~p~ v3 (novel) ^4^    *sed* v1 (pSAP074A)                *sed*~aa~ v1 (pSAP074A)         Human infection                  CC5/t002     \[[@B30-toxins-08-00169]\]                                       
  BW10     pSK67       *sed*~p~ v2                *sed* v2                           *sed*~aa~ v2                    SFP                              CC45/t383    Medical Department of the German Federal Armed Forces, Germany   
  RKI1     pSK67       *sed*~p~ v2                *sed* v2                           *sed*~aa~ v2                    SFP                              CC8/t648     Robert Koch Institute, Germany                                   
  RKI2     pSK67       *sed*~p~ v2                *sed* v2                           *sed*~aa~ v2                    SFP                              CC8/t008     Robert Koch Institute, Germany                                   
  SAR35    novel ^4^   *sed*~p~ v1 (pSAP074A)     *sed* v2 (pSK67)                   *sed*~aa~ v2 (pSK67)            Bovine mastitis milk             CC8/t2953    \[[@B32-toxins-08-00169]\]                                       
  SAK8     novel ^4^   *sed*~p~ v1 (pSAP074A)     *sed* v3 (p502A)                   *sed*~aa~ v3 (p502A)            Rabbit                           CC5/t179     \[[@B31-toxins-08-00169]\]                                       
  SAK9     novel ^4^   ND ^5^                     *sed* v3 (p502A)                   *sed*~aa~ v3 (p502A)            Rabbit                           CC5/t8456    \[[@B31-toxins-08-00169]\]                                       
  SAK11    novel ^4^   *sed*~p~ v1 (pSAP074A)     *sed* v3 (p502A)                   *sed*~aa~ v3 (p502A)            Rabbit                           CC5/t179     \[[@B31-toxins-08-00169]\]                                       
  SAK13    novel ^4^   *sed*~p~ v1 (pSAP074A)     *sed* v3 (p502A)                   *sed*~aa~ v3 (p502A)            Rabbit                           CC5/t179     \[[@B31-toxins-08-00169]\]                                       
  SAK18    novel ^4^   ND ^5^                     *sed* v3 (p502A)                   *sed*~aa~ v3 (p502A)            Rabbit                           CC5/t8456    \[[@B31-toxins-08-00169]\]                                       
  SAK64    novel ^4^   ND ^5^                     *sed* v3 (p502A)                   *sed*~aa~ v3 (p502A)            Rabbit                           CC5/t160     \[[@B31-toxins-08-00169]\]                                       
  SANC30   novel ^4^   *sed*~p~ v1 (pSAP074A)     *sed* v4 (novel)^4^                *sed*~aa~ v4 (novel) ^4^        Human nasal colonization         CC5/t002     \[[@B30-toxins-08-00169]\]                                       

^1^ Reference sequences were obtained from GenBank. Accession numbers: CP000046.1 (strain COL), AB716349.1 (strain IVM10), AB716351.1 (strain No. 10), CP010952.1 (strain 93b_S9), CP010944.1 (strain 79_S10), AJ938182.1 (strain RF122), KF386012.1 (strain B1085), CP007659.1 (strain H-EMRSA-15), GQ900426.1, (plasmid pSAP074A), CP007455.1 (plasmid p502A), GQ900447.1 (plasmid pSK67); ^2^ Nucleotide sequence; ^3^ SFP = Staphylococcal Food Poisoning; ^4^ Novel variant with no identical reference sequence available in GenBank; ^5^ Not determined.

toxins-08-00169-t002_Table 2

###### 

Overview of pairwise amino acid identity of the different SEB, SEC, and SED variants. The novel variant 4 of SED (*sed*~aa~ v4) was detected in a strain isolated from a nasal carrier and has not been previously described.

  Variant      SEB v1   SEB v2   SEB v3   SEC-1   SEC-2   SEC-3   SEC-4   SEC-bovine   SEC-ovine   SED v1   SED v2   SED v3   SED v4
  ------------ -------- -------- -------- ------- ------- ------- ------- ------------ ----------- -------- -------- -------- --------
  SEB v1       100      99       97       68      67      69      67      69           67          36       35       25       36
  SEB v2       \-       100      98       67      66      67      66      68           67          36       36       25       36
  SEB v3       \-       \-       100      67      66      67      66      68           67          36       35       24       35
  SEC-1        \-       \-       \-       100     97      94      97      99           98          32       32       22       32
  SEC-2        \-       \-       \-       \-      100     96      99      97           96          33       32       22       32
  SEC-3        \-       \-       \-       \-      \-      100     96      94           93          33       33       23       33
  SEC-4        \-       \-       \-       \-      \-      \-      100     97           96          33       33       22       33
  SEC-bovine   \-       \-       \-       \-      \-      \-      \-      100          99          32       32       22       32
  SEC-ovine    \-       \-       \-       \-      \-      \-      \-      \-           100         32       32       21       32
  SED v1       \-       \-       \-       \-      \-      \-      \-      \-           \-          100      99       66       99
  SED v2       \-       \-       \-       \-      \-      \-      \-      \-           \-          \-       100      66       99
  SED v3       \-       \-       \-       \-      \-      \-      \-      \-           \-          \-       \-       100      65
  SED v4       \-       \-       \-       \-      \-      \-      \-      \-           \-          \-       \-       \-       100
